Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Telix and Regeneron partner to develop radiopharmaceutical therapies for solid tumors.
Telix Pharmaceuticals and Regeneron Pharmaceuticals have partnered to co-develop and commercialize next-generation radiopharmaceutical therapies for solid tumors.
The agreement includes an upfront payment of $40 million and potential milestone payments of up to $2.1 billion.
The companies will share costs and profits equally, focusing on precision oncology and leveraging Regeneron's antibody discovery technology.
18 Articles
Telix y Regeneron se asociaron para desarrollar terapias radiofarmacéuticas para tumores sólidos.